Recombinant multi-species VEGFA protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine VEGFA protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. The levels of VEGF are increased during infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), thus promoting inflammation by facilitating recruitment of inflammatory cells, and by increasing the level of angiopoietin II (Ang II), one of two products of the SARS-CoV-2 binding target, angiotensin-converting enzyme 2 (ACE2). In turn, Ang II facilitates the elevation of VEGF, thus forming a vicious cycle in the release of inflammatory cytokines. [provided by RefSeq, Jun 2020]
The Alternative Names of target: L-VEGF,MVCD1,VEGF,VEGF-A,VEGF111,VEGF164,VEGFA,VPF,Vascular endothelial growth factor A,Vascular permeability factor (VPF),Vegf,Vegfa,Vpf,eVEGF120,eVEGF164,long form

Target products collectionGo to VEGFA products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-T20761-Ag-1/ GM-Tg-hg-T20761-Ag-2 Human VEGFA protein Human
GM-Tg-rg-T20761-Ag-1/ GM-Tg-rg-T20761-Ag-2 Rat VEGFA protein Rat
GM-Tg-mg-T20761-Ag-1/ GM-Tg-mg-T20761-Ag-2 Mouse VEGFA protein Mouse
GM-Tg-cynog-T20761-Ag-1/ GM-Tg-cynog-T20761-Ag-2 Cynomolgus/Rhesus macaque VEGFA protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-T20761-Ag-1/ GM-Tg-felg-T20761-Ag-2 Feline VEGFA protein Feline
GM-Tg-cang-T20761-Ag-1/ GM-Tg-cang-T20761-Ag-2 Canine VEGFA protein Canine
GM-Tg-bovg-T20761-Ag-1/ GM-Tg-bovg-T20761-Ag-2 Bovine VEGFA protein Bovine
GM-Tg-equg-T20761-Ag-1/ GM-Tg-equg-T20761-Ag-2 Equine VEGFA protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-T20761-Ag-1/ GM-Tg-hg-T20761-Ag-2; GM-Tg-rg-T20761-Ag-1/ GM-Tg-rg-T20761-Ag-2;
GM-Tg-mg-T20761-Ag-1/ GM-Tg-mg-T20761-Ag-2; GM-Tg-cynog-T20761-Ag-1/ GM-Tg-cynog-T20761-Ag-2;
GM-Tg-felg-T20761-Ag-1/ GM-Tg-felg-T20761-Ag-2; GM-Tg-cang-T20761-Ag-1/ GM-Tg-cang-T20761-Ag-2;
GM-Tg-bovg-T20761-Ag-1/ GM-Tg-bovg-T20761-Ag-2; GM-Tg-equg-T20761-Ag-1/ GM-Tg-equg-T20761-Ag-2
Products Name VEGFA protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name VEGFA
Protein Sub-location Secreted Protein/Potential Cytokines
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine VEGFA protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.